<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35067114</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1360-0451</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>AIDS care</Title><ISOAbbreviation>AIDS Care</ISOAbbreviation></Journal><ArticleTitle>AC-2020-12-1420.R1 - HIV care providers' familiarity, concerns, and attitudes about HIV PrEP in Colombia: insights from the PrEP-Col-Study.</ArticleTitle><Pagination><StartPage>1428</StartPage><EndPage>1434</EndPage><MedlinePgn>1428-1434</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/09540121.2022.2029813</ELocationID><Abstract><AbstractText>In 2019, Colombia approved the combination of tenofovir disoproxil fumarate/emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP). Therefore, we conducted a situational analysis in HIV-care providers to identify barriers and facilitators for PrEP implementation. A survey was applied to a non-probabilistic sample of health care workers of HIV-specialized clinics. We examined PrEP awareness and familiarity, comfort with PrEP-related activities, perceived barriers for PrEP implementation, concerns, and attitudes. Poisson regressions assessed the relationship between these factors and the variable "having a plan to offer PrEP". The participation rate was 41% and included physicians (42.6%) and other health professionals (57.4%). Fifty-one percent of the participants reported more than five years of experience caring for people living with HIV. Forty-two percent of non-physician health care workers were nurses. Most reported high familiarity/comfort with PrEP-relevant activities. Concerns about PrEP were prevalent (&gt; 50%) and included causing more harm than good, reducing condom use, medication non-adherence, drug resistance, and healthcare system barriers. Physicians had a plan to offer PrEP (72.2%) more often than other health professionals (52.6). Having a plan to offer PrEP was related to PrEP knowledge and comfort assessing sexual behavior and providing HIV counseling. Overall, about half of HIV-care providers seemed ready to offer PrEP and constitute an asset for PrEP implementation efforts in Colombia. PrEP awareness among non-physicians, PrEP concerns, and negative attitudes need to be addressed to enhance implementation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mart&#xed;nez-Cajas</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2847-7823</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Queen's University, Kingston, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarado-Llano</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1269-405X</Identifier><AffiliationInfo><Affiliation>Department of Public Health Sciences, Queen's University, Kingston, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Buitrago</LastName><ForeName>Ernesto</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0959-8593</Identifier><AffiliationInfo><Affiliation>Hospital Universitario del Valle Evaristo Garc&#xed;a, Unidad de Epidemiolog&#xed;a, Universidad del Valle, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres-Isasiga</LastName><ForeName>Julian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6477-9867</Identifier><AffiliationInfo><Affiliation>Albert Einstein College of Medicine and Montefiore Medical Center, Division of Infectious Diseases, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arrivillaga</LastName><ForeName>Marcela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5927-3386</Identifier><AffiliationInfo><Affiliation>Pontificia Universidad Javeriana, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camargo</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-8349-7723</Identifier><AffiliationInfo><Affiliation>Queen's University, School of Nursing. Kingston Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galindo-Orrego</LastName><ForeName>Ximena</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-0422-9200</Identifier><AffiliationInfo><Affiliation>Corporaci&#xf3;n de Lucha Contra el SIDA, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mueses-Mar&#xed;n</LastName><ForeName>H&#xe9;ctor</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-0608-6656</Identifier><AffiliationInfo><Affiliation>Corporaci&#xf3;n de Lucha Contra el SIDA, Cali, Colombia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>AIDS Care</MedlineTA><NlmUniqueID>8915313</NlmUniqueID><ISSNLinking>0954-0121</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="Y">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="Y">HIV Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003105" MajorTopicYN="N" Type="Geographic">Colombia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007722" MajorTopicYN="N">Health Knowledge, Attitudes, Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065129" MajorTopicYN="Y">Pre-Exposure Prophylaxis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HIV Pre-Exposure Prophylaxis (PrEP)</Keyword><Keyword MajorTopicYN="N">HIV prevention</Keyword><Keyword MajorTopicYN="N">Implementation science</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>24</Day><Hour>5</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35067114</ArticleId><ArticleId IdType="doi">10.1080/09540121.2022.2029813</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>